NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
25.59
+0.67 (2.69%)
Sep 2, 2026, 4:00 PM EDT - Market closed
NAMS Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7.12 | 22.5 | 45.56 | 14.09 | 102.69 | - | |
Revenue Growth | -88.87% | -50.61% | 223.37% | -86.28% | - | - |
Gross Profit | 7.12 | 22.5 | 45.56 | 14.09 | 102.69 | - |
Selling, General & Admin | 102.28 | 106.35 | 70.45 | 37.63 | 19.51 | 6 |
Research & Development | 149.25 | 141.83 | 151.41 | 159.42 | 86.74 | 28.97 |
Operating Expenses | 251.53 | 248.19 | 221.85 | 197.06 | 106.25 | 34.98 |
Operating Income | -244.41 | -225.68 | -176.29 | -182.97 | -3.56 | -34.98 |
Interest Expense | - | - | - | - | -0.29 | -0.41 |
Interest & Investment Income | 24.65 | 27.59 | 16.88 | 11.28 | - | - |
Currency Exchange Gain (Loss) | -2 | 13.06 | -6.6 | 5.06 | -9.75 | 1.71 |
Other Non Operating Income (Expenses) | -37.74 | -22.78 | -38.58 | -10.02 | -8.34 | -7.22 |
EBT Excluding Unusual Items | -259.5 | -207.81 | -204.59 | -176.64 | -21.93 | -40.9 |
Other Unusual Items | - | 3.99 | -37.01 | -0.27 | -0.71 | -0.88 |
Pretax Income | -259.5 | -203.82 | -241.6 | -176.91 | -22.63 | -41.79 |
Income Tax Expense | - | - | -0 | 0.03 | - | - |
Net Income | -259.5 | -203.82 | -241.6 | -176.94 | -22.63 | -41.79 |
Net Income to Common | -259.5 | -203.82 | -241.6 | -176.94 | -22.63 | -41.79 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 121 | 118 | 94 | 82 | 19 | 11 |
Shares Outstanding (Diluted) | 121 | 118 | 94 | 82 | 19 | 11 |
Shares Change | 12.87% | 25.50% | 14.84% | 333.20% | 72.75% | 119.58% |
EPS (Basic) | -2.14 | -1.72 | -2.56 | -2.15 | -1.19 | -3.81 |
EPS (Diluted) | -2.14 | -1.72 | -2.56 | -2.15 | -1.19 | -3.81 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -143.72 | -148.03 | -159.24 | -141.24 | 10.44 | -29.54 |
Free Cash Flow Per Share | -1.19 | -1.25 | -1.69 | -1.72 | 0.55 | -2.69 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Operating Margin | -3432.20% | -1002.90% | -386.91% | -1298.56% | -3.46% | - |
Profit Margin | -3644.21% | -905.74% | -530.25% | -1255.76% | -22.04% | - |
Free Cash Flow Margin | -2018.28% | -657.82% | -349.49% | -1002.43% | 10.17% | - |
EBITDA | -244.16 | -225.46 | -176.18 | -182.92 | -3.55 | -34.97 |
EBITDA Margin | - | - | - | - | -3.45% | - |
D&A For EBITDA | 0.24 | 0.22 | 0.11 | 0.05 | 0.01 | 0.01 |
EBIT | -244.41 | -225.68 | -176.29 | -182.97 | -3.56 | -34.98 |
EBIT Margin | - | - | - | - | -3.46% | - |